
AcelRx Pharmaceuticals (ACRX) shares have been up recently as the company awaits an FDA decision on its product Zalviso. Zalviso has already received approval in the European Union, but the FDA previously requested the company to do an additional trial to address certain concerns. AcelRx successfully completed the additional trial and expects the FDA to approve Zalviso this week. Here’s a recap.